Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Journal of Translational Medicine
Published in: Journal of Translational Medicine 1/2011

Open Access 01-12-2011 | Review

Ozone acting on human blood yields a hormetic dose-response relationship

Authors: Velio A Bocci, Iacopo Zanardi, Valter Travagli

Published in: Journal of Translational Medicine | Issue 1/2011

Login to get access

Abstract

The aim of this paper is to analyze why ozone can be medically useful when it dissolves in blood or in other biological fluids. In reviewing a number of clinical studies performed in Peripheral Arterial Diseases (PAD) during the last decades, it has been possible to confirm the long-held view that the inverted U-shaped curve, typical of the hormesis concept, is suitable to represent the therapeutic activity exerted by the so-called ozonated autohemotherapy. The quantitative and qualitative aspects of human blood ozonation have been also critically reviewed in regard to the biological, therapeutic and safety of ozone. It is hoped that this gas, although toxic for the pulmonary system during prolonged inhalation, will be soon recognized as a useful agent in oxidative-stress related diseases, joining other medical gases recently thought to be of therapeutic importance. Finally, the elucidation of the mechanisms of action of ozone as well as the obtained results in PAD may encourage clinical scientists to evaluate ozone therapy in vascular diseases in comparison to the current therapies.
Appendix
Available only for authorised users
Literature
1.
Xia L, Lenaghan SC, Zhang M, Zhang Z, Li Q: Naturally occurring nanoparticles from English ivy: an alternative to metal-based nanoparticles for UV protection. J Nanobiotechnology. 2010, 8: 12-10.1186/1477-3155-8-12.PubMedCentralCrossRefPubMed
2.
Bell ML, McDermott A, Zeger SL, Samet JM, Dominici F: Ozone and short-term mortality in 95 US urban communities, 1987-2000. JAMA. 2004, 292 (19): 2372-2378. 10.1001/jama.292.19.2372.PubMedCentralCrossRefPubMed
3.
Jerrett M, Burnett RT, Pope CA, Ito K, Thurston G, Krewski D, Shi Y, Calle E, Thun M: Long-term ozone exposure and mortality. N Engl J Med. 2009, 360 (11): 1085-1095. 10.1056/NEJMoa0803894.PubMedCentralCrossRefPubMed
4.
Bocci V, Borrelli E, Travagli V, Zanardi I: The ozone paradox: ozone is a strong oxidant as well as a medical drug. Med Res Rev. 2009, 29 (4): 646-682. 10.1002/med.20150.CrossRefPubMed
5.
Bocci V, Di Paolo N: Oxygen-ozone therapy in medicine: an update. Blood Purif. 2009, 28 (4): 373-376. 10.1159/000236365.CrossRefPubMed
6.
Guven A, Gundogdu G, Vurucu S, Uysal B, Oztas E, Ozturk H, Korkmaz A: Medical ozone therapy reduces oxidative stress and intestinal damage in an experimental model of necrotizing enterocolitis in neonatal rats. J Pediatr Surg. 2009, 44 (9): 1730-1735. 10.1016/j.jpedsurg.2009.01.007.CrossRefPubMed
7.
Morsy MD, Hassan WN, Zalat SI: Improvement of renal oxidative stress markers after ozone administration in diabetic nephropathy in rats. Diabetol Metab Syndr. 2010, 13 (2(1)): 29-CrossRef
8.
Steppan J, Meaders T, Muto M, Murphy KJ: A metaanalysis of the effectiveness and safety of ozone treatments for herniated lumbar discs. J Vasc Interv Radiol. 2010, 21 (4): 534-548. 10.1016/j.jvir.2009.12.393.CrossRefPubMed
9.
Demirbag S, Uysal B, Guven A, Cayci T, Ozler M, Ozcan A, Kaldirim U, Surer I, Korkmaz A: Effects of medical ozone therapy on acetaminophen-induced nephrotoxicity in rats. Ren Fail. 2010, 32 (4): 493-497. 10.3109/08860221003646352.CrossRefPubMed
10.
Uysal B, Yasar M, Ersoz N, Coskun O, Kilic A, Cayc T, Kurt B, Oter S, Korkmaz A, Guven A: Efficacy of hyperbaric oxygen therapy and medical ozone therapy in experimental acute necrotizing pancreatitis. Pancreas. 2010, 39 (1): 9-15. 10.1097/MPA.0b013e3181bb5ae3.CrossRefPubMed
11.
Di Filippo C, Luongo M, Marfella R, Ferraraccio F, Lettieri B, Capuano A, Rossi F, D'Amico M: Oxygen/ozone protects the heart from acute myocardial infarction through local increase of eNOS activity and endothelial progenitor cells recruitment. Naunyn Schmiedebergs Arch Pharmacol. 2010, 382 (3): 287-291. 10.1007/s00210-010-0545-2.CrossRefPubMed
12.
Timbrell J: The poison paradox: chemicals as friends and foes. 2005, New York: Oxford University Press
13.
Olivieri G, Bodycote J, Wolff S: Adaptive response of human lymphocytes to low concentrations of radioactive thymidine. Science. 1984, 223 (4636): 594-597. 10.1126/science.6695170.CrossRefPubMed
14.
Wolff S: Aspects of the adaptive response to very low doses of radiation and other agents. Mutat Res. 1996, 358 (2): 135-142.CrossRefPubMed
15.
Goldman M: Cancer risk of low-level exposure. Science. 1996, 271 (5257): 1821-1822. 10.1126/science.271.5257.1821.CrossRefPubMed
16.
Calabrese EJ, Baldwin LA: A general classification of U-shaped dose-response relationships in toxicology and their mechanistic foundations. Hum Exp Toxicol. 1998, 17 (7): 353-364. 10.1191/096032798678908918.CrossRefPubMed
17.
Calabrese EJ, Baldwin LA: Defining hormesis. Hum Exp Toxicol. 2002, 21 (2): 91-97. 10.1191/0960327102ht217oa.CrossRefPubMed
18.
Calabrese EJ: Hormesis: principles and applications for pharmacology and toxicology. Am J Pharm Toxicol. 2008, 3 (1): 56-68.
19.
Calabrese EJ: Hormesis is central to toxicology, pharmacology and risk assessment. Hum Exp Toxicol. 2010, 29 (4): 249-261.CrossRefPubMed
20.
Bocci V: Oxygen-Ozone Therapy: A Critical Evaluation. 2002, Dordrecht, The Netherlands: Kluwer Academic PublisherCrossRef
21.
Bocci V: Is it true that ozone is always toxic? The end of a dogma. Toxicol Appl Pharmacol. 2006, 216 (3): 493-504. 10.1016/j.taap.2006.06.009.CrossRefPubMed
22.
Bocci V: The case for oxygen-ozonetherapy. Br J Biomed Sci. 2007, 64 (1): 44-49.PubMed
23.
Re L: La terapia con ossigeno-ozono o ozormesi: recenti acquisizioni scientifiche. Medici & Medici. 2008, 16: 18-20.
24.
Horvath M, Bilitzky L, Huttner J: Ozone. 1985, New York: Elsevier
25.
Wolff HH: Das medizinische Ozon. Theoretische Grundlagen, therapeutische Anwendungen. 1998, Heidelberg: Verlag für Medizin Fischer
26.
Bocci V: Ozone. A new medical drug. 2011, Dordrecht, The Netherlands: Springer
27.
Aldini G, Gamberoni L, Orioli M, Beretta G, Regazzoni L, Maffei Facino R, Carini M: Mass spectrometric characterization of covalent modification of human serum albumin by 4-hydroxy-trans-2-nonenal. J Mass Spectrom. 2006, 41 (9): 1149-1161. 10.1002/jms.1067.CrossRefPubMed
28.
Aldini G, Vistoli G, Regazzoni L, Gamberoni L, Facino RM, Yamaguchi S, Uchida K, Carini M: Albumin is the main nucleophilic target of human plasma: a protective role against pro-atherogenic electrophilic reactive carbonyl species?. Chem Res Toxicol. 2008, 21 (4): 824-835. 10.1021/tx700349r.CrossRefPubMed
29.
Bocci V: Scientific and medical aspects of ozone therapy. State of the art. Arch Med Res. 2006, 37 (4): 425-435. 10.1016/j.arcmed.2005.08.006.CrossRefPubMed
30.
Shinriki N, Suzuki T, Takama K, Fukunaga K, Ohgiya S, Kubota K, Miura T: Susceptibilities of plasma antioxidants and erythrocyte constituents to low levels of ozone. Haematologia (Budap). 1998, 29 (3): 229-239.
31.
Poli G, Schaur RJ, Siems WG, Leonarduzzi G: 4-Hydroxynonenal: A membrane lipid oxidation product of medicinal interest. Med Res Rev. 2008, 28 (4): 569-631. 10.1002/med.20117.CrossRefPubMed
32.
Guichardant M, Bacot S, Molière P, Lagarde M: Hydroxy-alkenals from the peroxidation of n-3 and n-6 fatty acids and urinary metabolites. Prostaglandins Leukot Essent Fatty Acids. 2006, 75 (3): 179-182. 10.1016/j.plefa.2006.05.006.CrossRefPubMed
33.
Long EK, Picklo MJ: Trans-4-hydroxy-2-hexenal, a product of n-3 fatty acid peroxidation: Make some room HNE... Free Radic Biol Med. 2010, 49 (1): 1-8. 10.1016/j.freeradbiomed.2010.03.015.CrossRefPubMed
34.
Bocci V, Valacchi G, Corradeschi F, Fanetti G: Studies on the biological effects of ozone: 8. Effects on the total antioxidant status and on interleukin-8 production. Mediators Inflamm. 1998, 7 (5): 313-317. 10.1080/09629359890820.PubMedCentralCrossRefPubMed
35.
Valacchi G, Bocci V: Studies on the biological effects of ozone: 11. Release of factors from human endothelial cells. Mediators Inflamm. 2000, 9 (6): 271-276. 10.1080/09629350020027573.PubMedCentralCrossRefPubMed
36.
Antunes F, Cadenas E: Estimation of H2O2 gradients across biomembranes. FEBS Lett. 2000, 475 (2): 121-126. 10.1016/S0014-5793(00)01638-0.CrossRefPubMed
37.
Stone JR, Collins T: The role of hydrogen peroxide in endothelial proliferative responses. Endothelium. 2002, 9 (4): 231-238. 10.1080/10623320214733.CrossRefPubMed
38.
Bocci V, Aldinucci C: Biochemical modifications induced in human blood by oxygenation-ozonation. J Biochem Mol Toxicol. 2006, 20 (3): 133-138. 10.1002/jbt.20124.CrossRefPubMed
39.
Stone JR, Yang S: Hydrogen peroxide: A signaling messenger. Antioxid Redox Signal. 2006, 8 (3-4): 243-70. 10.1089/ars.2006.8.243.CrossRefPubMed
40.
Mendiratta S, Qu ZC, May JM: Erythrocyte ascorbate recycling: Antioxidant effects in blood. Free Radic Biol Med. 1998, 24 (5): 789-797. 10.1016/S0891-5849(97)00351-1.CrossRefPubMed
41.
Bocci V, Luzzi E, Corradeschi F, Paulesu L, Rossi R, Cardaioli E, Di Simplicio P: Studies on the biological effects of ozone: 4. Cytokine production and glutathione levels in human erythrocytes. J Biol Regul Homeost Agents. 1993, 7 (4): 133-138.PubMed
42.
Packer L, Roy S, Sen CK: Alpha-lipoic acid: A metabolic antioxidant and potential redox modulator of transcription. Adv Pharmacol. 1997, 38: 79-101.CrossRefPubMed
43.
Rokitanski O, Rokitanski A, Steiner J, Trubel W, Viebahn R, Washüttl J: Die ozontherapie bei peripheren, arteriellen Durchblutungs-strörugen; klinik, biochemische und blutgasanalytische untersuchungen. Wasser IOA. 1981, Ozon-Weltkongress: Berlin, 53-75.
44.
Bocci V, Larini A, Micheli V: Restoration of normoxia by ozone therapy may control neoplastic growth: a review and a working hypothesis. J Altern Complement Med. 2005, 11 (2): 257-265. 10.1089/acm.2005.11.257.CrossRefPubMed
45.
Babior BM, Takeuchi C, Ruedi J, Gutierrez A, Wentworth P: Investigating antibody-catalyzed ozone generation by human neutrophils. Proc Natl Acad Sci USA. 2003, 100 (6): 3031-3034. 10.1073/pnas.0530251100.PubMedCentralCrossRefPubMed
46.
Shin HW, Umber BJ, Meinardi S, Leu SY, Zaldivar F, Blake DR, Cooper DM: Acetaldehyde and hexanaldehyde from cultured white cells. J Transl Med. 2009, 7: 31-10.1186/1479-5876-7-31.PubMedCentralCrossRefPubMed
47.
Volkhovskaya NB, Tkachenko SB, Belopolsky AA: Modulation of phagocytic activity of blood polynuclear leukocytes with ozonized physiological saline. Bull Exp Biol Med. 2008, 146 (5): 559-561. 10.1007/s10517-009-0340-6.CrossRefPubMed
48.
Sen R, Baltimore D: Inducibility of kappa immunoglobulin enhancer-binding protein Nf-kappa B by a posttranslational mechanism. Cell. 1986, 47 (6): 921-928. 10.1016/0092-8674(86)90807-X.CrossRefPubMed
49.
Baeuerle PA, Henkel T: Function and activation of NF-kappa B in the immune system. Annu Rev Immunol. 1994, 12: 141-79. 10.1146/annurev.iy.12.040194.001041.CrossRefPubMed
50.
Bocci V, Paulesu L: Studies on the biological effects of ozone 1. Induction of interferon gamma on human leucocytes. Haematologica. 1990, 75 (6): 510-515.PubMed
51.
Burgassi S, Zanardi I, Travagli V, Montomoli E, Bocci V: How much ozone bactericidal activity is compromised by plasma components?. J Appl Microbiol. 2009, 106 (5): 1715-1721. 10.1111/j.1365-2672.2008.04141.x.CrossRefPubMed
52.
Valacchi G, Bocci V: Studies on the biological effects of ozone: 10. Release of factors from ozonated human platelets. Mediators Inflamm. 1999, 8 (4-5): 205-9. 10.1080/09629359990360.PubMedCentralCrossRefPubMed
53.
Petersen DR, Doorn JA: Reactions of 4-hydroxynonenal with proteins and cellular targets. Free Radic Biol Med. 2004, 37 (7): 937-945. 10.1016/j.freeradbiomed.2004.06.012.CrossRefPubMed
54.
Bocci V, Valacchi G, Corradeschi F, Aldinucci C, Silvestri S, Paccagnini E, Gerli R: Studies on the biological effects of ozone: 7. Generation of reactive oxygen species (ROS) after exposure of human blood to ozone. J Biol Regul Homeost Agents. 1998, 12 (3): 67-75.PubMed
55.
Siems W, Grune T: Intracellular metabolism of 4-hydroxynonenal. Mol Aspects Med. 2003, 24 (4-5): 167-175. 10.1016/S0098-2997(03)00011-6.CrossRefPubMed
56.
Awasthi YC, Ansari GA, Awasthi S: Regulation of 4-hydroxynonenal mediated signaling by glutathione S-transferase. Methods Enzymol. 2005, 401: 379-407.CrossRefPubMed
57.
Petras T, Siems W, Grune T: 4-Hydroxynonenal is degraded to mercapturic acid conjugate in rat kidney. Free Radic Biol Med. 1995, 19 (5): 685-688. 10.1016/0891-5849(95)00060-B.CrossRefPubMed
58.
Alary J, Geuraud F, Cravedi JP: Fate of 4-hydroxynonenal in vivo: Disposition and metabolic pathways. Mol Aspects Med. 2003, 24 (4-5): 177-187. 10.1016/S0098-2997(03)00012-8.CrossRefPubMed
59.
Jardines D, Correa T, Ledea O, Zamora Z, Rosado A, Molerio J: Gas chromatography-mass spectrometry profile of urinary organic acids of Wistar rats orally treated with ozonized unsaturated triglycerides and ozonized sunflower oil. J Chromatogr B Analyt Technol Biomed Life Sci. 2003, 783 (2): 517-525. 10.1016/S1570-0232(02)00707-9.CrossRefPubMed
60.
Bocci V: Does ozone therapy normalize the cellular redox balance? Implications for therapy of human immunodeficiency virus infection and several other diseases. Med Hypotheses. 1996, 46 (2): 150-154. 10.1016/S0306-9877(96)90016-X.CrossRefPubMed
61.
Takahashi K, Hara E, Ogawa K, Kimura D, Fujita H, Shibahara S: Possible implications of the induction of human heme oxygenase-1 by nitric oxide donors. J Biochem. 1997, 121 (6): 1162-1168.CrossRefPubMed
62.
Dianzani MU: 4-Hydroxynonenal and cell signalling. Free Radic Res. 1998, 28 (6): 553-560. 10.3109/10715769809065811.CrossRefPubMed
63.
Lin F, Josephs SF, Alexandrescu DT, Ramos F, Bogin V, Gammill V, Dasanu CA, De Necochea-Campion R, Patel AN, Carrier E, Koos DR: Lasers, stem cells, and COPD. J Transl Med. 2010, 8: 16-10.1186/1479-5876-8-16.PubMedCentralCrossRefPubMed
64.
Bocci V, Aldinucci C, Mosci F, Carraro F, Valacchi G: Ozonation of human blood induces a remarkable upregulation of heme oxygenase-1 and heat stress protein-70. Mediators Inflamm. 2007, 2007: 26785-PubMedCentralCrossRefPubMed
65.
Chaudhary P, Sharma R, Sharma A, Vatsyayan R, Yadav S, Singhal SS, Rauniyar N, Prokai L, Awasthi S, Awasthi YC: Mechanisms of 4-hydroxy-2-nonenal induced pro- and anti-apoptotic signaling. Biochemistry. 2010, 49 (29): 6263-6275.PubMedCentralCrossRefPubMed
66.
Taha H, Skrzypek K, Guevara I, Nigisch A, Mustafa S, Grochot-Przeczek A, Ferdek P, Was H, Kotlinowski J, Kozakowska M, Balcerczyk A, Muchova L, Vitek L, Weigel G, Dulak J, Jozkowicz A: Role of heme oxygenase-1 in human endothelial cells: lesson from the promoter allelic variants. Arterioscler Thromb Vasc Biol. 2010, 30 (8): 1634-1641. 10.1161/ATVBAHA.110.207316.PubMedCentralCrossRefPubMed
67.
Wang R: Two's company, three's a crowd: can H2S be the third endogenous gaseous transmitter?. FASEB J. 2002, 16 (13): 1792-1798. 10.1096/fj.02-0211hyp.CrossRefPubMed
68.
69.
Calabrese EJ, Stanek EJ, Nascarella MA, Hoffmann GR: Hormesis predicts low-dose responses better than threshold models. Int J Toxicol. 2008, 27 (5): 369-378. 10.1080/10915810802503735.CrossRefPubMed
70.
Bocci V, Zanardi I, Travagli V: Potentiality of oxygen-ozone therapy to improve the health of aging people. Curr Aging Sci. 2010, 3 (3): 177-187. 10.2174/1874609811003030177.CrossRefPubMed
71.
Michaud K, Matheson K, Kelly O, Anisman H: Impact of stressors in a natural context on release of cortisol in healthy adult humans: a meta-analysis. Stress. 2008, 11 (3): 177-197. 10.1080/10253890701727874.CrossRefPubMed
72.
Viru A, Tendzegolskis Z: Plasma endorphin species during dynamic exercise in humans. Clin Physiol. 1995, 15 (1): 73-79.CrossRefPubMed
73.
Travagli V, Zanardi I, Silvietti A, Bocci V: A physicochemical investigation on the effects of ozone on blood. Int J Biol Macromol. 2007, 41 (5): 504-511. 10.1016/j.ijbiomac.2007.06.010.CrossRefPubMed
74.
Travagli V, Zanardi I, Bernini P, Nepi S, Tenori L, Bocci V: Effects of ozone blood treatment on the metabolite profile of human blood. Int J Toxicol. 2010, 29 (2): 165-174. 10.1177/1091581809360069.CrossRefPubMed
75.
Hunter PE, Krithayakiern V: Effect of gamma radiation upon life expectancy and reproduction in the house cricket, Acheta domesticus (Orthoptera: Gryllidae). Ann. Entomol. Soc. America. 1971, 64: 119-123.CrossRef
76.
Meng Z: Effects of arsenic on DNA synthesis in human lymphocytes. Arch Environ Contam Toxicol. 1993, 25 (4): 525-528.CrossRefPubMed
77.
Tang L, Mamotte CD, Van Bockxmeer FM, Taylor RR: The effect of homocysteine on DNA synthesis in cultured human vascular smooth muscle. Atherosclerosis. 1998, 136 (1): 169-173. 10.1016/S0021-9150(97)00208-6.CrossRefPubMed
78.
Rattan SIS, Demirovic D: Hormesis and aging. Hormesis: A Revolution in Biology, Toxicology and Medicine. Edited by: Mattson MP and Calabrese E. Totowa NJ. 2010, Humana Press, Springer Science and Business Media, 153-175.CrossRef
79.
Re R, Pellegrini N, Proteggente A, Pannala A, Yang M, Rice-Evans C: Antioxidant activity applying an improved ABTS radical cation decolorization assay. Free Radic Biol Med. 1999, 26 (9-10): 1231-1237. 10.1016/S0891-5849(98)00315-3.CrossRefPubMed
80.
Matassi R, D'Angelo F, Bisetti P, Colombo R, Vaghi M: Terapia con ozono per via parenterale nelle arteriopatie obliteranti periferiche: Meccanismo biochimico e risultati clinici. Il Giornale di Chirurgia. 1987, VIII: 109-111.
81.
Hernández F, Menéndez S, Wong R: Decrease of blood cholesterol and stimulation of antioxidative response in cardiopathy patients treated with endovenous ozone therapy. Free Radic Biol Med. 1995, 19 (1): 115-119. 10.1016/0891-5849(94)00201-T.CrossRefPubMed
82.
Di Paolo N, Bocci V, Garosi G, Borrelli E, Bravi A, Bruci A, Aldinucci C, Capotondo L: Extracorporeal blood oxygenation and ozonation (EBOO) in man. Preliminary report. Int J Artif Organs. 2000, 23 (2): 131-41.PubMed
83.
Biedunkiewicz B, Tylicki L, Nieweglowski T, Burakowski S, Rutkowski B: Clinical efficacy of ozonated autohemotherapy in hemodialyzed patients with intermittent claudication: An oxygen-controlled study. Int J Artif Organs. 2004, 27 (1): 29-34.PubMed
84.
De Monte A, van der Zee H, Bocci V: Major ozonated autohemotherapy in chronic limb ischemia with ulcerations. J Altern Complement Med. 2005, 11 (2): 363-367. 10.1089/acm.2005.11.363.CrossRefPubMed
85.
Di Paolo N, Bocci V, Salvo DP, Palasciano G, Biagioli M, Meini S, Galli F, Ciari I, Maccari F, Cappelletti F, Di Paolo M, Gaggiotti E: Extracorporeal blood oxygenation and ozonation (EBOO): a controlled trial in patients with peripheral artery disease. Int J Artif Organs. 2005, 28 (10): 1039-1050.PubMed
86.
Bocci V, Zanardi I, Travagli V: Ozone: A New Therapeutic Agent in Vascular Diseases. Am J Cardiovasc Drugs. 2011, 11 (2): 73-82. 10.2165/11539890-000000000-00000.CrossRefPubMed
87.
Martínez-Sánchez G, Pérez-Davison G, Re L, Giuliani A: Ozone as U-shaped dose responses molecules (Hormetins). Dose Response. 2011, 9 (1): 32-49. 10.2203/dose-response.10-001.Martinez-Sanchez.PubMedCentralCrossRef
88.
Bocci V, Zanardi I, Huijberts MSP, Travagli V: Diabetes and chronic oxidative stress. A perspective based on the possible usefulness of ozone therapy. Diab Met Syndr: Clin Res Rev. 2011, 5 (1): 45-49. 10.1016/j.dsx.2010.05.014.CrossRef
89.
90.
Valacchi G, Lim Y, Belmonte G, Miracco C, Zanardi I, Bocci V, Travagli V: Ozonated sesame oil enhances cutaneous wound healing in SKH1 mice. Wound Repair Regen. 2011, 19 (1): 107-115. 10.1111/j.1524-475X.2010.00649.x.CrossRefPubMed
91.
Galli F: Protein damage and inflammation in uraemia and dialysis patients. Nephrol Dial Transplant. 2007, 22 (suppl 5): v20-36.CrossRefPubMed
92.
Ruggenenti P, Schieppati A, Remuzzi G: Progression, remission, regression of chronic renal diseases. Lancet. 2001, 357 (9268): 1601-1608. 10.1016/S0140-6736(00)04728-0.CrossRefPubMed
93.
Calunga JL, Trujillo Y, Menéndez S, Zamora Z, Alonso Y, Merino N, Montero T: Ozone oxidative post-conditioning in acute renal failure. J Pharm Pharmacol. 2009, 61 (2): 221-227.CrossRefPubMed
94.
Bocci V, Zanardi I, Michaeli D, Travagli V: Mechanisms of action and chemical-biological interactions between ozone and body compartments: a critical appraisal of the different administration routes. Curr Drug Ther. 2009, 4 (3): 159-173. 10.2174/157488509789055045.CrossRef
95.
Grocott MP, Martin DS, Levett DZ, McMorrow R, Windsor J, Montgomery HE, Caudwell Xtreme Everest Research Group: Arterial blood gases and oxygen content in climbers on Mount Everest. N Engl J Med. 2009, 360 (2): 140-149. 10.1056/NEJMoa0801581.CrossRefPubMed
Metadata
Title
Ozone acting on human blood yields a hormetic dose-response relationship
Authors
Velio A Bocci
Iacopo Zanardi
Valter Travagli
Publication date
01-12-2011
Publisher
BioMed Central
Published in
Journal of Translational Medicine / Issue 1/2011
Electronic ISSN: 1479-5876
DOI
https://doi.org/10.1186/1479-5876-9-66

Other articles of this Issue 1/2011

Journal of Translational Medicine 1/2011 Go to the issue

Commentary

CD4saurus Rex &HIVelociraptor vs. development of clinically useful immunological markers: a Jurassic tale of frozen evolution

Research

Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy improves survival of gastric cancer with peritoneal carcinomatosis: evidence from an experimental study

Research

Circulating CD133+CD34+ progenitor cells inversely correlate with soluble ICAM-1 in early ischemic stroke patients

Research

Complement component C5a Promotes Expression of IL-22 and IL-17 from Human T cells and its Implication in Age-related Macular Degeneration

Research

Antibodies against insulin measured by electrochemiluminescence predicts insulitis severity and disease onset in non-obese diabetic mice and can distinguish human type 1 diabetes status

Research

Endogenous interleukin-10 constrains Th17 cells in patients with inflammatory bowel disease
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits